DRUG STUDY

BRAND NAME, GENERIC Prescribed and Mechanism

NAME, CLASSIFICATION Recommended dosage, Of
frequency, route of Action Indication Contraindication Adverse Reaction Nursing Responsibilities
administration

GENERIC NAME Prescribed dosage Piperacillin: Binds to Treatment of Hypersensitive to drug CNS: headache,  Assess patient for
bacterial cell wall moderate to severe and other pencillins, insomnia, fever, seizures, infection at
Piperacillin + 424 mg IVTT drip q6hrs bacterial infections, cephalosporins or beta- agitation, anxiety, beginning of and
membrane, causing cell
Tazobactam including lactamase inhibitors dizziness, pain during therapy.
Recommended dosage death. Spectrum is
community  Obtain a history
extended compared with acquired/nosocomial CV: Arrhythmia, chest before initiating
4.5 gm q6h IV other penicillins. pain, edema, HTN,
pneumonia. therapy to determine
ROUTE: Tazobactam: Inhibits tachycardia previous use of and
BRAND NAME beta- lactamase, an reactions to penicillin
IV, IM GI: diarrhea, or cephalosporins.
enzyme that can destroy constipation, nausea,
Zosyn penicillins  Obtain specimens for
abdominal pain, culture and
dyspepsia, vomiting sensitivity prior to
Respiratory: Dyspnea initiating therapy.
CLASSIFICATION
 Observe patient for
Pharmacological: Hematologic: Anemia, signs and symptoms
Extended-spectrum thrombocytopenia of anaphylaxis.
penicillins – beta –  Discontinue the drug
lactamase inhibitors Skin: Pruritus, rash and notify physician
immediately if these
Other: Anaphylaxis,  occur. Keep
Therapeutic: Antibiotic
hypersensitivity epinephrine, and
reactions, inflammation, resuscitation
phlebitis at IV site. equipment close by
in the event of an
anaphylactic
reaction.
 Monitor bowel
function. Diarrhea,
abdominal cramping,
fever, and bloody
stools should be
reported to physician
promptly as a sign of
CDAD.
  Assess for skin
reactions.Monitor
patient with mild to
moderate rash for
progression.
 If rash becomes
severe or systemic
symptoms occur,
discontinue
piperacillin/tazobacta
m.

DRUG STUDY

BRAND NAME GENERIC Prescribed and Mechanism

NAME CLASSIFICATION Recommended dosage, Of
frequency, route of Action Indication Contraindication Adverse Reaction Nursing Responsibilities
administration
GENERIC NAME: Prescribed dosage Inhibit protein synthesis  Treatment of serious Contraindications: CNS: Drowsiness, Before:
Amikacin in susceptible bacteria by infections (bone Hypersensitivity to tremors, fever, headache
27mg IVTT q8h  Assess for
binding 30S ribosomal infections, amikacin, other GI: Diarrhea, nausea and hypersensitivity to
Recommended dosage unit, leading to an respiratory tract aminoglycosides vomiting aminoglycoside
antibacterial effect. infections) due to  Correct dehydration
BRAND NAME: IV, IM: Children 5-7.5 Pseudomonas, other Cautions: Preexisting Metabolic: Weight loss before therapy begins
mg q8h because of increased
Therapeutic effect: gram-negative renal impairment,
Skin: Rash risk of toxicity
Amikin Neonates 15mg q12-48h Interferes with protein organisms. hypocalcemia,
(based on weight)  Mycobacterium neuromuscular disorder Other: Phlebitis, Rash,
synthesis of susceptible
avium complex Fever
ROUTE: IV, IM microorganisms.
(MAC) During:
CLASSIFICATION:
Pharmacological:  Monitor I&O
Aminoglycosides  Check IM injection
site for pain, evaluate
IV site for phlebitis
Therapeutic: Antibiotic
 Assess for skin rash,
diarrhea and
superinfections

After:

 Document drug given

 Note for adverse
reactions after drug
administration